NCT02694393View on ClinicalTrials.gov

Inhaled Sodium Nitrite as an Antimicrobial for Cystic Fibrosis

PHASE1/PHASE2TerminatedINTERVENTIONAL

Enrollment

4

Participants

Timeline

Start Date

February 29, 2016

Primary Completion Date

July 21, 2022

Study Completion Date

July 21, 2022

Conditions

Cystic Fibrosis

Interventions

DRUG

sodium nitrite

inhalation of 46 or 80 mg of sodium nitrite by electronic nebulization

Trial Locations (2)

15213

Children's Hospital of Pittsburgh, Pittsburgh

Comprehensive Lung Center - Falk Clinic, Pittsburgh

Sponsors

Collaborators (1)

Mast Therapeutics, Inc.

All Listed Sponsors

collaborator

Mast Therapeutics, Inc.

INDUSTRY

collaborator

Cystic Fibrosis Foundation

OTHER

lead

Schmidhofer, Mark, MD

INDIV

NCT02694393 - Inhaled Sodium Nitrite as an Antimicrobial for Cystic Fibrosis | Biotech Hunter | Biotech Hunter